# Gujarat Themis Biosyn股票在5月25日可能持續成為焦點。

*biotech, business · news · 2026-05-25 · Moneycontrol*

## Key points

- Gujarat Themis Biosyn將收購MicroBiopharm Japan Co., Ltd. 100%股權。
- 收購價格為215億日圓（約1300億盧比），由債務和股權融資組成。
- 該交易預計於2027財年第二季度完成，需待監管批准及交割條件達成。
- 收購將通過在日本新成立的特殊目的載體進行。

Gujarat Themis Biosyn shares are likely to remain in focus on May 25 after the company announced the acquisition of 100% equity stake in MicroBiopharm Japan Co., Ltd., a Japan-based company with more than six decades of expertise in fermentation, microbial-based research, development, and manufacturing of pharmaceuticals and specialty chemicals. The company has signed a definitive agreement to acquire the entire shareholding of MicroBiopharm Japan from funds managed or advised by T Capital Partners Co., Ltd.. The acquisition will be carried out through a wholly owned Special Purpose Vehicle (SPV) to be incorporated in Japan. According to the company, the transaction is expected to be completed during Q2FY27, subject to customary regulatory approvals and closing conditions. The total acquisition cost stands at JPY 21.5 billion (approximately ₹1,300 crore) and will be financed through an optimal combination of debt and equity. Catch all the market action on our live blog Meanwhile, the board of directors of Gujarat Themis Biosyn is scheduled to meet on May 25, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a dividend on the company’s equity shares for FY26, if any. In the previous trading session, the share closed at Rs 368.85, up Rs 11.75, or 3.29 percent. The share touched a 52-week high of Rs 479.45 and a 52-week low of Rs 225.75 on 27 October, 2025 and 30 March, 2026, respectively. Currently, the stock is trading 23.07 percent below its 52-week high and 63.39 percent above its 52-week low. The market capitalisation of the company stands at Rs 4,019.18 crore.

**Companies:** Gujarat Themis Biosyn
**Countries:** Japan, India

[Read the full story on Moneycontrol](https://www.moneycontrol.com/news/business/stocks/gujarat-themis-biosyn-in-focus-after-rs-1-300-crore-acquisition-deal-for-japanese-firm-13929171.html)

---

Canonical: https://newsio.io/zh-TW/n/b1773b07-0a3f-4dcd-a8a9-b19bc84da3ce/gujarat-themis-biosyn525microbiopharm-japan-co-ltd-100
Summarized by Newsio from Moneycontrol. https://newsio.io/how-it-works